Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Candel TherapeuticsCADL +7.38%30 OCF Yield % is -6.41 as of Jul. 18, 2026. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Candel Therapeutics ranks better than 53.97% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Candel Therapeutics OCF Yield % Related Terms
Candel Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Candel Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Candel Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Candel Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics (CADL) has a OCF Yield % of -6.41 as of Jul. 18, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Candel Therapeutics and its competitors. According to the industry distribution chart, Candel Therapeutics ranks #649 out of 1410 companies in the Biotechnology industry, placing it in the top 46%.
Is Candel Therapeutics' OCF Yield % too high?
Candel Therapeutics' current OCF Yield % is -6.41. Based on the distribution chart, Candel Therapeutics ranks #649 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' OCF Yield % compare to AURA and RIGL?
According to the Biotechnology industry distribution chart, Candel Therapeutics ranks #649 out of 1410 companies for OCF Yield %. This puts Candel Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current OCF Yield % is -6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current OCF Yield % of -6.41. The current OCF Yield % is -6.41. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current OCF Yield % is -6.41 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score
Get the complete analysis for CADL
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CADL has been successfully added to your 
